Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 96

1.

CLINICAL EVALUATION OF COST EFFICACY OF DRUGS FOR TREATMENT OF OSTEOPOROSIS: A META-ANALYSIS.

Albert SG, Reddy S.

Endocr Pract. 2017 Jul;23(7):841-856. doi: 10.4158/EP161678.RA. Epub 2017 Apr 27. Review.

PMID:
28448754
2.

Indirect comparison of teriparatide, denosumab, and oral bisphosphonates for the prevention of vertebral and nonvertebral fractures in postmenopausal women with osteoporosis.

Zhang L, Pang Y, Shi Y, Xu M, Xu X, Zhang J, Ji L, Zhao D.

Menopause. 2015 Sep;22(9):1021-5. doi: 10.1097/GME.0000000000000466.

PMID:
25944523
3.

Prevention of bone loss with risedronate in breast cancer survivors: a randomized, controlled clinical trial.

Greenspan SL, Vujevich KT, Brufsky A, Lembersky BC, van Londen GJ, Jankowitz RC, Puhalla SL, Rastogi P, Perera S.

Osteoporos Int. 2015 Jun;26(6):1857-64. doi: 10.1007/s00198-015-3100-7. Epub 2015 Mar 20.

4.

Anti-reabsorptive agents in women with osteoporosis: determining statistical equivalence according to evidence-based methods.

Messori A, Fadda V, Maratea D, Trippoli S, Marinai C.

J Endocrinol Invest. 2014 Aug;37(8):769-73. doi: 10.1007/s40618-014-0124-3. Epub 2014 Jul 10.

PMID:
25008458
5.

Indirect comparison of bazedoxifene vs oral bisphosphonates for the prevention of vertebral fractures in postmenopausal osteoporotic women.

Ellis AG, Reginster JY, Luo X, Bushmakin AG, Williams R, Sutradhar S, Mirkin S, Jansen JP.

Curr Med Res Opin. 2014 Aug;30(8):1617-26. doi: 10.1185/03007995.2014.908279. Epub 2014 May 2. Review.

PMID:
24773456
6.

Factors associated with bisphosphonate treatment failure in postmenopausal women with primary osteoporosis.

Cairoli E, Eller-Vainicher C, Ulivieri FM, Zhukouskaya VV, Palmieri S, Morelli V, Beck-Peccoz P, Chiodini I.

Osteoporos Int. 2014 Apr;25(4):1401-10. doi: 10.1007/s00198-014-2619-3. Epub 2014 Feb 8.

PMID:
24510095
7.

Osteoporotic vertebral fractures during pregnancy: be aware of a potential underlying genetic cause.

Campos-Obando N, Oei L, Hoefsloot LH, Kiewiet RM, Klaver CC, Simon ME, Zillikens MC.

J Clin Endocrinol Metab. 2014 Apr;99(4):1107-11. doi: 10.1210/jc.2013-3238. Epub 2014 Jan 13.

PMID:
24423337
8.

Treatment of osteoporosis in men with bisphosphonates: rationale and latest evidence.

Sim IeW, Ebeling PR.

Ther Adv Musculoskelet Dis. 2013 Oct;5(5):259-67. doi: 10.1177/1759720X13500861.

9.

Effects of risedronate alone or combined with vitamin K2 on serum undercarboxylated osteocalcin and osteocalcin levels in postmenopausal osteoporosis.

Kasukawa Y, Miyakoshi N, Ebina T, Aizawa T, Hongo M, Nozaka K, Ishikawa Y, Saito H, Chida S, Shimada Y.

J Bone Miner Metab. 2014 May;32(3):290-7. doi: 10.1007/s00774-013-0490-5. Epub 2013 Jul 12.

PMID:
23846118
10.

Comparison of teriparatide and bisphosphonate treatment to reduce pedicle screw loosening after lumbar spinal fusion surgery in postmenopausal women with osteoporosis from a bone quality perspective.

Ohtori S, Inoue G, Orita S, Yamauchi K, Eguchi Y, Ochiai N, Kishida S, Kuniyoshi K, Aoki Y, Nakamura J, Ishikawa T, Miyagi M, Kamoda H, Suzuki M, Kubota G, Sakuma Y, Oikawa Y, Inage K, Sainoh T, Takaso M, Toyone T, Takahashi K.

Spine (Phila Pa 1976). 2013 Apr 15;38(8):E487-92. doi: 10.1097/BRS.0b013e31828826dd.

PMID:
23354115
11.

A novel monthly dosing regimen of risedronate for the treatment of postmenopausal osteoporosis: 2-year data.

McClung MR, Benhamou CL, Man Z, Tlustochowicz W, Zanchetta JR, Eusebio R, Balske AM, Matzkin E, Olszynski WP, Recker R, Delmas PD.

Calcif Tissue Int. 2013 Jan;92(1):59-67. doi: 10.1007/s00223-012-9668-4. Epub 2012 Nov 13.

12.

Teriparatide accelerates lumbar posterolateral fusion in women with postmenopausal osteoporosis: prospective study.

Ohtori S, Inoue G, Orita S, Yamauchi K, Eguchi Y, Ochiai N, Kishida S, Kuniyoshi K, Aoki Y, Nakamura J, Ishikawa T, Miyagi M, Kamoda H, Suzuki M, Kubota G, Sakuma Y, Oikawa Y, Inage K, Sainoh T, Takaso M, Ozawa T, Takahashi K, Toyone T.

Spine (Phila Pa 1976). 2012 Nov 1;37(23):E1464-8. doi: 10.1097/BRS.0b013e31826ca2a8.

PMID:
22872218
13.

The effect of teriparatide compared with risedronate on reduction of back pain in postmenopausal women with osteoporotic vertebral fractures.

Hadji P, Zanchetta JR, Russo L, Recknor CP, Saag KG, McKiernan FE, Silverman SL, Alam J, Burge RT, Krege JH, Lakshmanan MC, Masica DN, Mitlak BH, Stock JL.

Osteoporos Int. 2012 Aug;23(8):2141-50. doi: 10.1007/s00198-011-1856-y. Epub 2011 Dec 13.

PMID:
22159672
14.

Effect of stopping risedronate after long-term treatment on bone turnover.

Eastell R, Hannon RA, Wenderoth D, Rodriguez-Moreno J, Sawicki A.

J Clin Endocrinol Metab. 2011 Nov;96(11):3367-73. doi: 10.1210/jc.2011-0412. Epub 2011 Aug 24.

15.

Vertebral fracture efficacy during risedronate therapy in patients using proton pump inhibitors.

Roux C, Goldstein JL, Zhou X, Klemes A, Lindsay R.

Osteoporos Int. 2012 Jan;23(1):277-84. doi: 10.1007/s00198-011-1574-5. Epub 2011 Mar 2.

PMID:
21365461
16.

Antifracture efficacy of currently available therapies for postmenopausal osteoporosis.

Reginster JY.

Drugs. 2011 Jan 1;71(1):65-78. doi: 10.2165/11587570-000000000-00000. Review.

17.

Sustained vertebral antifracture efficacy of oral anti-osteoporotic therapies in postmenopausal osteoporosis.

Brandi ML.

Curr Med Res Opin. 2010 Nov;26(11):2553-63. doi: 10.1185/03007995.2010.519658. Epub 2010 Sep 21. Review.

PMID:
20858031
18.

The efficacy of bisphosphonates in the prevention of vertebral, hip, and nonvertebral-nonhip fractures in osteoporosis: a network meta-analysis.

Jansen JP, Bergman GJ, Huels J, Olson M.

Semin Arthritis Rheum. 2011 Feb;40(4):275-84.e1-2. doi: 10.1016/j.semarthrit.2010.06.001. Epub 2010 Sep 9.

PMID:
20828791
19.

[Effects of SERMs on bone health. Discrimination of SERMs from bisphosphonates in the treatment of postmenopausal osteoporosis].

Iwamoto J.

Clin Calcium. 2010 Mar;20(3):396-407. doi: CliCa1003396407. Review. Japanese.

PMID:
20190370
20.

Risedronate decreases bone resorption and improves low back pain in postmenopausal osteoporosis patients without vertebral fractures.

Ohtori S, Akazawa T, Murata Y, Kinoshita T, Yamashita M, Nakagawa K, Inoue G, Nakamura J, Orita S, Ochiai N, Kishida S, Takaso M, Eguchi Y, Yamauchi K, Suzuki M, Aoki Y, Takahashi K.

J Clin Neurosci. 2010 Feb;17(2):209-13. doi: 10.1016/j.jocn.2009.06.013. Epub 2009 Dec 30.

PMID:
20044258

Supplemental Content

Loading ...
Support Center